Profile | GDS2987 / GI_5902091-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | 52 | 71 |
GSM215244 | HMVEC_vehicle_rep2 | 3.1 | 8 |
GSM215253 | HMVEC_vehicle_rep3 | 30 | 63 |
GSM215254 | HMVEC_atorvastatin_rep1 | 59.6 | 71 |
GSM215282 | HMVEC_atorvastatin_rep3 | 49.6 | 67 |
GSM215344 | HMVEC_atorvastatin_rep2 | 91.5 | 75 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 49.1 | 65 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 56.2 | 64 |
GSM215294 | HMVEC_SLx2119_rep1 | 50.2 | 71 |
GSM215295 | HMVEC_SLx2119_rep2 | 40.8 | 60 |
GSM215296 | HMVEC_SLx2119_rep3 | 27.1 | 42 |
GSM215297 | PASMC_vehicle_rep1 | 28.6 | 41 |
GSM215298 | PASMC_vehicle_rep2 | 3 | 5 |
GSM215310 | PASMC_vehicle_rep3 | 27 | 40 |
GSM215311 | PASMC_atorvastatin_rep1 | 33.3 | 50 |
GSM215312 | PASMC_atorvastatin_rep2 | 37.7 | 51 |
GSM215313 | PASMC_atorvastatin_rep3 | 24.3 | 35 |
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 20.9 | 34 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 2.3 | 4 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 29.8 | 46 |
GSM215327 | PASMC_SLx2119_rep1 | ||
GSM215328 | PASMC_SLx2119_rep2 | ||
GSM215329 | PASMC_SLx2119_rep3 | 18.2 | 34 |
GSM215330 | Fibroblasts_vehicle_rep1 | 11.4 | 27 |
GSM215331 | Fibroblasts_vehicle_rep2 | 36.5 | 63 |
GSM215332 | Fibroblasts_vehicle_rep3 | 36.4 | 65 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 33.5 | 62 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 29.6 | 59 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 36.2 | 61 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 33.2 | 64 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 36.5 | 66 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 29.5 | 59 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 50.4 | 69 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 34 | 63 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 50 | 68 |